Axoft makes Fleuron ultra-soft BCI material available for purchase and licenses to Stanford — new R&D ecosystem
Summary
Axoft announced that Fleuron — its ultra-soft neural implant material 10,000x softer than polyimide — is now available for purchase for R&D applications, and simultaneously announced an exclusive licensing deal with Stanford University for specific research applications. The commercialization of Fleuron as a standalone material creates a new market for BCI researchers who want to apply the biocompatible material to their own electrode designs, without using Axoft's full commercial BCI system.
Why it matters
Making Fleuron commercially available for R&D creates a new business model line for Axoft — material licensor in addition to BCI device developer. The Stanford licensing deal brings the world's most active BCI research campus into the Fleuron ecosystem, generating academic publications and clinical experience that will support Axoft's own regulatory submissions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial